Advisory Committee on Blood and Tissue Safety and Availability

Committee’s Official Designation

Advisory Committee on Blood and Tissue Safety and Availability (the Committee or ACBTSA)


The Advisory Committee on Blood and Tissue Safety and Availability is authorized under 42

U.S.C. 217a, Section 222 of the Public Health Service (PHS) Act, as amended. The Committee is governed by the provisions of the Federal Advisory Committee Act (FACA), Public Law 92- 463, as amended (5 U.S.C. App).

Objectives and Scope of Activities

The Secretary is responsible under Sections 301,351, and 361 of the PHS Act, as amended

(42 U.S.C. 241,262, 264), and various provisions of the Federal Food, Drugs and Cosmetic Act (21 U.S.C. 301 et seq.) for issuing and enforcing regulations concerning the collection, preparation, and distribution of blood, blood products, tissues and organs; for issuing and enforcing regulations related to the transmission of communicable diseases; and for carrying out research in health fields including diseases involving these products.

The ACBTSA will advise, assist, consult with, and make policy recommendations to the Secretary, through the Assistant Secretary for Health, regarding these broad responsibilities related to the safety of blood, blood products, tissues, and organs as further delineated under Description of Duties. For solid organs and blood stem cells, the Committee's work will be limited to policy issues related to donor derived infectious disease complications of transplantation.

Description of Duties

The Committee will provide advice on a range of policy issues to include:

  1. identification of public health issues through surveillance of blood and tissue safety;
  2. identification of public health issues that affect availability of blood, blood products, and tissues;
  3. broad public health, ethical and legal issues related to the safety of blood, blood products, and tissues;
  4. the impact of various economic factors (e.g., product cost and supply) on safety and availability of blood, blood products, and tissues;
  5. risk communications related to blood transfusion and tissue transplantation; and
  6. identification of infectious disease transmission issues for blood, tissue, organs, and blood stem cells.

Agency of Official to Whom the Committee Reports

The Committee will provide advice to the Secretary, through the Assistant Secretary for Health.


Management and support services for Committee activities will be provided by the Office of Infectious Disease and HIV/AIDS Policy (OIDP), which is a program office within Office of the Assistant Secretary for Health (OASH). The OASH is a staff division within Office of the Secretary in the Department of Health and Human Services (HHS).

Estimated Annual Operating Costs and Staff Years

Estimated annual cost for operating the Committee, including compensation and travel expenses for members, but excluding staff support, is $92,500. Estimated person years of staff support required is 2.0, at an estimated annual cost of $320,000.

Pursuant to an advance written agreement, the special government employee (SGE) voting members shall receive no stipend from the federal government for the services they perform during their tenure on the Advisory Council. However, the SGE voting members are entitled to receive per diem and reimbursement for travel expenses incurred for attending meetings of the Advisory Committee, as authorized by 5 U.S.C. Sec. 5703, as amended, for persons who are employed intermittently in the Government service. The non-voting liaison representative members may be allowed to receive per diem and any applicable expenses for travel that is performed to attend meetings of the Advisory Committee in accordance with federal travel regulations, as determined by the DFO.

Designated Federal Officer (DFO)

The Senior Advisor for Blood and Tissue Policy in the OASH/OIDP will serve as the DFO for the Committee. If the DFO cannot fulfill the responsibilities associated with this position for the Committee, then the Alternate DFO shall serve in this capacity and carry out the assigned duties for this position.

The DFO will schedule and approve all meetings of the Committee and any respective subcommittee meetings that are to be held. The DFO will prepare and approve all meeting agendas. Development of the meeting agenda can be done in collaboration with the Committee chair(s), and, when it is deemed appropriate, the chairs of any respective subcommittees of the Committee. The DFO will attend all meetings of the Committee and any respective subcommittees that are established to assist the Committee. The DFO also has authority to adjourn meetings, when it is determined to be in the public interest, and can be directed by the Assistant Secretary for Health or designee to chair meetings of the Committee.

Estimated Number and Frequency of Meetings

The Committee will meet not less than once a year. Meetings will be open to the public, except as determined otherwise by the Secretary or other official to whom authority has been delegated, in keeping with the guidelines under Government in the Sunshine Act, 5 U.S.C. 552b(c). The public will be given notification about Committee meetings that are scheduled to be held; notices to announce the meetings will be published in the Federal Register. Meetings will be conducted and records of the proceedings will be kept, as required by applicable laws and Departmental policies. A quorum of not less than one-half of the membership is required for the ACBTSA to meet to conduct business.

When it is determined by the Secretary, or other official to whom authority has been delegated, that a meeting will be closed or partially closed to the public, in accordance with stipulations of Government in the Sunshine Act, 5 U.S.C. 552b(c), then a report will be prepared that includes, at a minimum, a list of the members and their business addresses, the ACBTSA's function, date and place of the meeting, and a summary of the Committee's activities and recommendations made during the fiscal year. A copy of the report will be provided to the Department Committee Management Officer.




Unless renewed by appropriate action, the Committee will be terminated two years from the date the charter is filed.

Membership and Designation

The Advisory Committee will consist of up to 29 members, including the voting and non-voting members and the Chair and Vice Chair or Co-Chairs. One or more of these voting members will be selected to serve as Chair, with an option for Vice Chair or Co-Chairs. The Committee will consist of not more than 23 voting members, who represent a diverse group of patient advocates, subject matter experts, and health professionals. The Committee members may be invited to serve for overlapping terms of up to four years with the Charter being reviewed every two years.

A member may serve no more than 180 days after the expiration of the member's term, if a successor has not taken office.

Voting Members: Special Government Employees (SGEs)

The Committee composition will include up to fourteen (14) voting public members, who will be selected from state and local organizations, patient advocacy groups, provider organizations, academic researchers, ethicists, physicians, surgeons, scientists, risk communication experts, consumer advocates, and from among communities of persons who are frequent recipients of blood or blood products or who have received tissues or organs. While this document sets no prescribed formula for distribution of membership, every attempt will be made for equal and diverse representation. The public voting members, appointed by the Secretary or designee, will be classified as special government employees (SGEs) and are subject to government ethics rules.

Voting Members: Representatives

The Committee will also include up to nine (9) voting representative members who are designated to represent the blood, tissue and organ professional organizations and/or business sectors. These representative members will be selected from the Association for the Advancement of Blood & Biotherapies, American Association of Tissue Banks, the Eye Bank Association of America, the Association of Organ Procurement Organizations, and one of either the American National Red Cross or America's Blood Centers on a rotating basis. The Committee composition can include additional representation from either the plasma protein fraction community or a trade organization; a manufacturer of blood, plasma, or other tissue/organ test kits; a manufacturer of blood, plasma or other tissue/organ equipment; a major hospital organization; or a major hospital accreditation organization. Where more than one company produces a specified product or process, representatives from those companies will rotate on the same schedule as public members. All voting members of the Committee will be selected by the Secretary or designee.

Non-Voting Members: Regular Government Employees (RGE)

The Committee shall also include up to six (6) non-voting RGE members to represent various federal agencies involved in blood and tissue safety and availability: Centers for Disease Control and Prevention (CDC); Centers for Medicare and Medicaid Services (CMS); Food and Drug Administration (FDA); Health Resources and Services Administration (HRSA); National Institutes of Health (NIH); or their designees. Other HHS officials may be invited to participate as non-voting members, as the Secretary or designee deem necessary, to effectively carry out the Committee's function.

Members who are officers or employees of the United States government shall not receive compensation for their services on the Committee.


In carrying out its function, the Committee may establish subcommittees, with approval of the Secretary or designee, to provide assistance in carrying out work associated with the mission of the Committee. The subcommittees will be composed of members of the parent committee and/or non-member individuals who have expertise and knowledge regarding the topics and issues that are pertinent to the mission of the Committee. The established subcommittees may consider issues in accordance with the charge of the Committee, and will, as appropriate, make reports to the ACBTSA for consideration. The established subcommittees may not report directly to the Secretary or another federal official unless there is specific statutory authority for such reporting. The Department Committee Management Officer will be notified upon establishment of each subcommittee, and will be given information regarding its name, membership, function, cost, and estimated frequency of meetings.


Records of the Committee and any established subcommittees will be handled in accordance with General Records Schedule 6.2, Federal Advisory Committee Records or other approved agency records disposition schedule. Applicable records will be made available to the public for inspection and copying, subject to the Freedom of Information Act, 5 U.S.C. 552.

Filing Date:

October 9, 2022


September 29, 2022

Xavier Becerra

Secretary of Health and Human Services

Content created by Office of Infectious Disease and HIV/AIDS Policy (OIDP)
Content last reviewed